You are here

Restasis

AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat

AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat

Fierce Pharma

Flag link:

AbbVie revives DTC ads for dry eye med Restasis with a patient front and center

AbbVie revives DTC ads for dry eye med Restasis with a patient front and center

Fierce Pharma

dry eye disease

DTC advertising

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Supreme Court sends Allergan packing over Restasis tribal licensing strategy

Supreme Court sends Allergan packing over Restasis tribal licensing strategy

Fierce Pharma

Flag link:

Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy

Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy

Endpoints

Aurinia Pharmaceuticals

dry eye disease

Flag link:

Allergan nixes Texas plant expansion as Restasis generics loom

Allergan nixes Texas plant expansion as Restasis generics loom

Fierce Pharma

drug manufacturing

Flag link:

Allergan, Mohawk tribe request rehearing in sovereign immunity IPR case

Allergan, Mohawk tribe request rehearing in sovereign immunity IPR case

BioCentury

Flag link:

Federal judges ban Allergan’s sovereign immunity scheme in a slapdown that will bolster inter partes review for years to come

Federal judges ban Allergan’s sovereign immunity scheme in a slapdown that will bolster inter partes review for years to come

Endpoints

inter partes review

Flag link:

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Endpoints

dry eye disease

Flag link:

Allergan: This $64,000 Question Could Kill Restasis IPR Appeal

Allergan: This $64,000 Question Could Kill Restasis IPR Appeal

NY Shock Exchange

Flag link:

Allergan: Restasis Lawsuit From Kroger, Walgreens Could Cost Billions

Allergan: Restasis Lawsuit From Kroger, Walgreens Could Cost Billions

NY Shock Exchange

Flag link:

Allergan faces fresh woes with Restasis patents as Walgreen, retailers file lawsuit over ‘anticompetitive conduct’

Allergan faces fresh woes with Restasis patents as Walgreen, retailers file lawsuit over ‘anticompetitive conduct’

Endpoints

Flag link:

Allergan's much-maligned tribal licensing deal wins reprieve at appeals court

Allergan's much-maligned tribal licensing deal wins reprieve at appeals court

Fierce Pharma

Flag link:

Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire

Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire

Xtalks

dry eye disease

Flag link:

Tribe looks to stop patent board’s review of Restasis IP

Tribe looks to stop patent board’s review of Restasis IP

Drug Delivery Business News

intellectual property

Flag link:

Senators heap abuse on Allergan’s attempt at an end run around patent reviews, offer bill to stop ‘sham’

Senators heap abuse on Allergan’s attempt at an end run around patent reviews, offer bill to stop ‘sham’

Endpoints

inter partes review

Flag link:

Sovereign nonsense: Patent board joins the lineup of critics dissing Allergan’s ‘illusory’ IP deal with the Mohawks

Sovereign nonsense: Patent board joins the lineup of critics dissing Allergan’s ‘illusory’ IP deal with the Mohawks

Endpoints

Flag link:

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Fierce Pharma

Flag link:

FDA Denies 3rd Allergan Citizen Petition to Block Restasis Generics

FDA Denies 3rd Allergan Citizen Petition to Block Restasis Generics

RAPS.org

citizen petitions

Flag link:

Allergan axing 1,000-plus jobs, prepping for a painful onslaught of Restasis knockoffs

Allergan axing 1,000-plus jobs, prepping for a painful onslaught of Restasis knockoffs

Endpoints

Flag link:

Pages